Jay Shankar, MD
Nephrology · Victorville, CANPI 1164431318
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,838 of the $4,182 with a category attached, or 67.9%. It is spread thinly across 23 manufacturers, the largest accounting for just 23.8%. Reporting peaked in 2022 at $1,437 and has fallen 53.1% since, to $674 in 2025.
Across 123 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$994
- AstraZeneca$491
- Akebia Therapeutics Inc$388
- Otsuka America Pharmaceutical, Inc.$337
- Amgen$274
- Vifor Pharma, Inc.$267
- plus $1K from 17 others
Across 131 payments — averaging $11,687 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$809K
- AstraZeneca$186K
- Astrazeneca UK Limited$168K
- Eli Lilly$122K
- Bayer$108K
- Merck$43K
- plus $94K from 6 others
What the payments were for
- Consulting fees$99424%
- Food & beverage$2,83868%
- Education$241%
- Other$3278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 1 | $994 |
| AstraZeneca | 14 | $491 |
| Akebia Therapeutics Inc | 17 | $388 |
| Otsuka America Pharmaceutical, Inc. | 11 | $337 |
| Amgen(2 entities) | 13 | $274 |
| Vifor Pharma, Inc. | 10 | $267 |
| Welch Allyn | 2 | $206 |
| Calliditas Therapeutics US Inc. | 6 | $150 |
| OPKO Pharmaceuticals, LLC | 8 | $137 |
| Bayer | 7 | $135 |
| GSK | 5 | $130 |
| Ardelyx, Inc. | 7 | $130 |
| Baxter Healthcare | 1 | $121 |
| Fresenius USA Marketing, Inc. | 8 | $119 |
| Travere Therapeutics, Inc. | 4 | $101 |
| Boehringer Ingelheim | 2 | $39 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Nxstage Medical, Inc. | 1 | $29 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Novartis | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,182 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 52 | $122,056 |
| VeltassaPatiromer Calcium Sorbitex | 67 | $69,011 |
| AuryxiaFerric Citrate | 42 | $67,473 |
| Sevelamer Carbonate | 241 | $34,504 |
| LokelmaSodium Zirconium Cyclosilicate | 51 | $34,167 |
| XphozahTenapanor Hcl | 11 | $30,229 |
| Sevelamer Hcl | 17 | $27,090 |
| ProsolParenteral Amino Acid 20% No.1 | 107 | $16,235 |
| RayaldeeCalcifediol | 11 | $12,812 |
| Cinacalcet Hcl | 117 | $11,936 |
| FarxigaDapagliflozin Propanediol | 17 | $10,754 |
| EliquisApixaban | 14 | $9,944 |
| Calcium Acetate | 70 | $7,090 |
| ProcritEpoetin Alfa | 12 | $6,176 |
| Colchicine | 18 | $2,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $119 | $122,05652 claims |
| Akebia Therapeutics IncAuryxia | $388 | $67,47342 claims |
| AstraZenecaLokelma, Farxiga | $491 | $44,92268 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $137 | $12,81211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.
Other nephrology in Victorville
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.